Capricor Therapeutics (CAPR) Liabilities and Shareholders Equity (2010 - 2026)

Capricor Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $326.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 112.19% year-over-year to $326.3 million in Q1 2026; TTM through Mar 2026 was $942.2 million, a 106.87% increase from a year earlier, with the FY2025 full-year figure at $355.9 million, up 108.79% from the prior year.
• Liabilities and Shareholders Equity slipped to $326.3 million in Q1 2026 per CAPR's latest filing, from $355.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $355.9 million in Q4 2025 and bottomed at $37.2 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $58.7 million (2023), against an average of $110.0 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 31.11% in 2023 and surged 248.95% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $50.1 million in 2022, then rose by 17.25% to $58.7 million in 2023, then soared by 190.26% to $170.5 million in 2024, then jumped by 108.79% to $355.9 million in 2025, then fell by 8.33% to $326.3 million in 2026.
• Per Business Quant, the three latest CAPR Liabilities and Shareholders Equity figures stand at $326.3 million (Q1 2026), $355.9 million (Q4 2025), and $126.4 million (Q3 2025).